

ANALYZED BY:

Anresco Laboratories 1375 Van Dyke Avenue, San Francisco, CA 94124 C8-0000052-LIC



DISTRIBUTOR:
Metta Medical
C11-0001250-LIC

CULTIVATOR / MANUFACTURER:

Metta Medical

Sample No.:	1127448		Sample Increments:	13
Product Name:	Level - Hy	brid Protab -	Sample Weight /	6.84
Matrix	25PT2205	o14d9H2 ate (Orally	Incrément (g): Total Sample Weight (g):	88.92
Matrix.		d Concentrate)	Date Collected:	05/20/202
Batch #:	25PT2205	i14d9H2	Date Received:	05/23/202
Product- Batch Size (Units):	1414		Date Reported:	05/25/202
Source UID:		0020081000001212		
TEST SUMMAR	Y			
Cannabinoid Prof	ile:	S Pass	Microbiological Screen:	C Pass
Pesticide Residue	Screen:	♥ Pass	Residual Solvent Screen:	✓ Pass
Heavy Metal Scree	en:	Pass Pass	Foreign Material:	✓ Pass
Mycotoxin Screen	:	C Pass	Water Activity:	Pass

Cannabinoid Profile SPass

Method:	MF-CHEM-15
Instrument:	Liquid Chromatography Diode Array Detector (LC-DAD)
Limit of Detection	0.1333 mg/g
Limit of Quantification	0.4 mg/g

Cannabinoid	mg/g	%	mg/serving	mg/package	Status
∆8-THC	ND	ND	ND	ND	2
∆9-THC	151 83	15.183	26.19	1047.45	Pass
۵9- <mark>THC</mark> A	ND	ND	ND	ND	21-11 21-11
THCV	ND	ND	ND	ND	2
THCVA	ND	ND	ND	ND	-
CBD	<loq< td=""><td><loq< td=""><td><loq< td=""><td><loq< td=""><td><u></u></td></loq<></td></loq<></td></loq<></td></loq<>	<loq< td=""><td><loq< td=""><td><loq< td=""><td><u></u></td></loq<></td></loq<></td></loq<>	<loq< td=""><td><loq< td=""><td><u></u></td></loq<></td></loq<>	<loq< td=""><td><u></u></td></loq<>	<u></u>
CBDA	ND	ND	ND	ND	5
CBC	2.97	0.297	0 51	20.48	2
CBCA	ND	ND	ND	ND	z :
CBDV	ND	ND	ND	ND	¥1
CBG	5.39	0.539	0.93	37.19	5
CBGA	ND	ND	ND	ND	÷
CBN	1.14	0.114	020	7 84	<u>2</u>
Total THC	151 83	15.183	26.19	1047.45	π.
Total CBD	ND	ND	ND	ND	¥.
Total Cannabinoids	161 33	16.133	27.82	1112.96	π.
Total Active Cannabinoids	161 33	16.133	27.82	1112.96	Ξ.
Serving Weight (g)	0.17247				

Serving Weight (g) 0.1 Package Weight (g) 6.9

Microbiological Screen Ø Pass

Analyte	Method	Findings	Status	
Salmonella	AOAC 2016.01	Negative/1g	Pass	
STEC	3M MDS STEC/EAE	Negative/1g	Pass	

Pesticide Residue Screen 🔮 Pass

Method: MF-CHEM-13

Instrument: Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)

Analyte	LOD/LOQ (µg/g)	Findings (µg/g)	Limit (µg/g)	Status
Abamectin	0.04/0.10	ND	0.3	Pass
Acephate	0.02/0.06	ND	5.0	Pass
Acequinocyl	0.04/0.10	ND	4.0	Pass
Acetamiprid	0.02/0.06	ND	5.0	Pass

Anresco Laboratories www.anresco.com 1375 Van Dyke Ave, San Francisco, CA 94124 Sample #: 1127448 Batch #: 25PT220514d9H2 Page 1 of 4 Report ID: S-2

This document is intended only for the use of the party to whom it is addressed and may contain information that is privileged, confidential or protected from disclosure under applicable law. If you have received this document in error, please immediately notify us and return it to the address listed above.

05/25/2022

05/25/2022

05/25/2022



Analyte	LOD/LOQ (µg/g)	Findings (µg/g)	Limit (µg/g)	Status
Aldicarb	0.02/0.06	ND	0.02	Pass
Azoxystrobin	0.02/0.06	ND	40.0	Pass
Bifenazate	0.02/0.06	ND	5.0	Pass
Bifenthrin	0.04/0.10	ND	0.5	Pass
Boscalid	0.02/0.06	ND	10.0	Pass
Captan	0 2/0.6	ND	5.0	Pass
Carbaryl	0.02/0.06	ND	0.5	Pass
Carbofuran	0.02/0.06	ND	0.02	Pass
Chlorantraniliprole	0.02/0.06	ND	40.0	Pass
Chlordane	0.02/0.06	ND	0.02	Pass
Chlorfenapyr	0.02/0.08	ND	0.02	Pass
Chlorpyrifos	0.02/0.06	ND	0.02	Pass
Clofentezine	0.02/0.06	ND	0.5	Pass
Coumaphos	0.02/0.06	ND	0.02	Pass
Cyfluthrin	0.10/0 30	ND	1.0	Pass
Cypermethrin	0.10/0 30	ND	1.0	Pass
Daminozide	0.02/0.06	ND	0.02	Pass
DDVP (Dichlorvos)	0.02/0.06	ND	0.02	Pass
Diazinon	0.02/0.06	ND	0.2	Pass
Dimethoate	0.02/0.06	ND	0.02	Pass
Dimethomorph	0.02/0.06	ND	20.0	Pass
Ethoprop(hos)	0.02/0.06	ND	0.02	Pass
Etofenprox	0.02/0.06	ND	0.02	Pass
Etoxazole	0.02/0.06	ND	1.5	Pass
Fenhexamid	0.02/0.06	ND	1.5	Pass
	0.02/0.06	ND	0.02	Pass
Fenoxycarb	0.02/0.06	ND	2.0	Pass
Fenpyroximate		ND		
Fipronil Flonicamid	0.02/0.06		0.02	Pass Pass
		ND		
Fludioxonil	0.02/0.06	ND	30.0	Pass
Hexythiazox	0.02/0.06	ND	2.0	Pass
Imazalil	0.02/0.06	ND	0.02	Pass
Imidacloprid	0.02/0.06	ND	3.0	Pass
Kresoxim Methyl	0.02/0.06	ND	1.0	Pass
Malathion	0.02/0.06	ND	5.0	Pass
Metalaxyl	0.02/0.06	ND	15.0	Pass
Methiocarb	0.02/0.06	ND	0.02	Pass
Methomyl	0.02/0.06	ND	0.1	Pass
Methyl parathion	0.02/0.06	ND	0.02	Pass
Mevinphos	0.02/0.06	ND	0.02	Pass
Myclobutanil	0.02/0.06	ND	9.0	Pass
Naled	0.02/0.06	ND	0.5	Pass
Oxamyl	0.02/0.06	ND	0.2	Pass
Paclobutrazol	0.02/0.06	ND	0.02	Pass
Pentachloronitrobenzene	0.04/0.10	ND	0.2	Pass
Permethrins	0.10/0 30	ND	20.0	Pass
Phosmet	0.02/0.06	ND	0.2	Pass
Piperonyl Butoxide	0.02/0.06	ND	8.0	Pass
Prallethrin	0.04/0.10	ND	0.4	Pass
Propiconazole	0.02/0.06	ND	20.0	Pass
Propoxur	0.02/0.06	ND	0.02	Pass
Pyrethrins	0.10/0 30	ND	1.0	Pass
Pyridaben	0.02/0.06	ND	3.0	Pass
Spinetoram	0.02/0.06	ND	3.0	Pass
Spinosad	0.02/0.06	ND	3.0	Pass
Spiromesifen	0.04/0.10	ND	12.0	Pass
Spirotetramat	0.02/0.06	ND	13.0	Pass
Spiroxamine	0.02/0.06	ND	0.02	Pass
Tebuconazole	0.02/0.06	ND	2.0	Pass
Thiadoprid	0.02/0.06	ND	0.02	Pass
Thiamethoxam	0.02/0.06	ND	4.5	Pass
Trifloxystrobin	010210100		30.0	1033

Residual Solvent Screen **V**Pass

Method: USP OVI<467>

Instrument: Gas Chromatography Mass Spectrometry (GC/MS)

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
1,2-Dichloroethane	0 2/0.5	ND	1	Pass

Anresco Laboratories www.anresco.com 1375 Van Dyke Ave, San Francisco, CA 94124

Sample #: 1127448 Batch #: 25PT220514d9H2

05/25/2022

Page 2 of 4 Report ID: S-2

This document is intended only for the use of the party to whom it is addressed and may contain information that is privileged, confidential or protected from disclosure under applicable law. If you have received this document in error, please immediately notify us and return it to the address listed above.



Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
Acetone	67/200	ND	5000	Pass
Acetonitrile	67/200	ND	410	Pass
Benzene	0 2/0.5	ND	1	Pass
n-Butane	67/200	ND	5000	Pass
Chloroform	0 2/0.5	ND	1	Pass
Ethanol	67/200	ND	5000	Pass
Ethyl acetate	67/200	ND	5000	Pass
Ethylether	67/200	ND	5000	Pass
Ethylene oxide	0 2/0.5	ND	1	Pass
n-Heptane	67/200	ND	5000	Pass
n-Hexane	67/200	ND	290	Pass
Isopropyl alcohol	67/200	ND	5000	Pass
Methanol	67/200	ND	3000	Pass
Methylene chloride	0 2/0.5	ND	1	Pass
n-Pentane	67/200	ND	5000	Pass
Propane	67/200	ND	5000	Pass
Toluene	67/200	ND	890	Pass
Total xylenes (ortho-, meta-, para-)	67/200	ND	2170	Pass
Trichloroethylene	0 2/0.5	ND	1	Pass

Heavy Metal Screen SPass

Method: MF-CHEM-16

Instrument: Inductively Coupled Plasma Mass Spectrometry (ICP-MS)

Analyte	LOD/LOQ (µg/g)	Findings (µg/g)	Limit (µg/g)	Status
Arsenic	0.02/0.05	ND	1.5	Pass
Cadmium	0.02/0.05	ND	0.5	Pass
Mercury	0.02/0.05	ND	3	Pass
Lead	0.02/0.05	ND	0.5	Pass

Foreign Material 🔮 Pass

Method: MF-MACRO-5

Analyte	Findings	Limit	Status	
Sand, Soils, Cinders, and Dirt	ND	25%	Pass	
Mold	ND	25%	Pass	
Imbedded Foreign Material	ND	25%	Pass	
Insect Fragment	ND	1 per 3g	Pass	
Hair	ND	1 per 3g	Pass	
Mammalian Excreta	ND	1 per 3g	Pass	

Mycotoxin Screen Ø Pass

Method: MF-CHEM-13

Instrument: Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)

Analyte	LOD/LOQ (µg/kg)	Findings (µg/kg)	Limit (µg/kg)	Status
Aflatoxin B1	2/5	ND	2	12
Aflatoxin B2	2/5	ND	5	-
Aflatoxin G1	2/5	ND	<u></u>	5.
Aflatoxin G2	2/5	ND	3	-
Total Aflatoxins	8/20	ND	20	Pass
Ochratoxin A	6/20	ND	20	Pass

Water Activity

Method: MF 14G 051

Instrument: Decagon

Analyte	Findings	Limit	Status
Water Activity	0 30	0 85	Pass

Anresco Laboratories www.anresco.com 1375 Van Dyke Ave, San Francisco, CA 94124 Sample #: 1127448 Batch #: 25PT220514d9H2 Page 3 of 4 Report ID: S-2

This document is intended only for the use of the party to whom it is addressed and may contain information that is privileged, confidential or protected from disclosure under applicable law. If you have received this document in error, please immediately notify us and return it to the address listed above.

05/25/2022

05/25/2022

05/24/2022

05/25/2022



() = Not Tested, ND = None Detected, <LOQ = Below Limit of Quantitation, LOD = Limit of Detection

All LQC samples were performed and met the acceptance criteria in CCR Title 4 Division 19. Chapter 6. Article 7. §15730. pursuant to §15726.(e)(13).

Reported by



Lab Co Director May 25, 2022

This document is intended only for the use of the party to whom it is addressed and may contain information that is privileged, confidential or protected from disclosure under applicable law. If you have received this document in error, please immediately notify us and return it to the address listed above.

